Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of AZD9833 with Midazolam, Omeprazole, Celecoxib, and Dabigatran in Healthy Women
NCT05438303Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of camizestrant in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity, Area under the plasma concentration curve from zero to the last quantifiable concentration and 1 more. Started Jun 2022; status: completed.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05438303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438303.